Press Releases

Completed 28-day safety study in Alzheimer’s disease patients and clinical drug-drug interaction study provide evidence to support the safety, tolerability and metabolic profile of ALX-001, a first-in-class oral therapy in clinical development for Alzheimer’s disease and Parkinson’s disease

Funding will support metabolism studies of ALX-001, a first-in-class oral therapy in clinical development for Alzheimer’s disease and Parkinson’s disease.

Allyx continues to advance clinical research of its first-in-class oral compound for neurodegenerative diseases

Growing body of clinical evidence ALX-001 is Ready to Commence Phase 2 Studies

US Senator Chris Murphy (D-Conn.) announced that Allyx Therapeutics, a clinical-stage biotechnoloyg company based in New Haven, was named "Innovator of the Month" for their ongoing development of a novel therapeutic approach for Alzheimer's and Parkinson's disease.

Safety of ALX-001 Reinforced by New Data presented at AD/PD 2024 Conference in Lisbon.

Two Oral Doses Selected for Further Study in Alzheimer's and Parkinson's Disease Patients

Recently Completed Multiple Ascending Dose Study of ALX-001 in Healthy Volunteers Sets Stage to Begin Further Studies in Alzheimer's and Parkinson's Disease Patients in 2024

New Phase 1a Clinical Data Presented on October 27 at the 16th Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development

Allyx's lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in neurodegenerative diseases.

New clinical data to be presented on October 17

Allyx Therapeutics expects to advance ALX-001, an mGluR5 modulator for Alzheimer's disease, into clinical trials in 2021

In The News

Hartford Business Journal | June 16, 2026

After raising $62M, New Haven biotech Allyx Therapeutics advances experimental Alzheimer's drug

Neurology Live | March 14, 2024

Potential of mGluR5 Modifier ALX-001 in Neurodegenerative Disorders

Yale News | July 5, 2017

Drug restores cells and memories in Alzhiemer's mouse models

Neurology Live | July 6, 2024

Synapse-Targeted Agent ALX-001 Ready for Phase 2 Following Early-Stage Progress

Neurology Live | November 14, 2023

Mechanistic Potential of Synpase-Targeted Agent ALX-001 for Alzheimer's Disease: Adam Mecca, MD, PhD

New Haven Register | September 4, 2013

Yale discovery could lead to Alzheimer's drug, restored memory

2024 Michael J. Fox Foundation Parkinson's Disease Therapeutics Conference - October 17, 2024

Evaluating the Pre-clinical Efficacy of a mGluR5 Silent Allosteric Modulator, ALX-001 (BMS-984923) in Parkinson's Disease Models and Initiation of a First-in-Patient Phase 1b Study

Presented by Tim Siegert, PhD

View the Presentation

AD/PD 2024 International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders - March 9, 2024

A Phase 1b Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALX-001, and mGluR5 Silent Allosteric Modulator, in Healthy Older Adults

Presented by Tim Siegert, PhD

View the Presentation

16th Clinical Trials on Alzheimer's Disease - October 7, 2023

A Phase 1a Single Ascending Dose Study of the Safety, Tolerability, and Brain Receptor Occupancy of ALX-001 in Healthy Older Adults

Presented by Adam Mecca, MD, PhD

Read the Abstract

Press Releases

Allyx Therapeutics Announces Successful Completion of Two Additional Studies of Lead Candidate ALX-001

Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001

Allyx Therapeutics Announces First Parkinson's Disease Patient Treated with ALX-001

Allyx Therapeutics Announces First Alzheimer's Disease Patient Treated with Lead Compound ALX-001

Murphy Highlights New Haven's Allyx Therapeutics as "Innovator of the Month"

Allyx Therapeutics Announces Positive Phase 1b Mulitple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics Announces Expansion into Parkinson's Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting

Allyx Therapeutics Announces License For the Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb and Yale